Soleus Capital Management L.P. Purchases 645,000 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Soleus Capital Management L.P. boosted its position in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 5.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 12,484,876 shares of the company’s stock after purchasing an additional 645,000 shares during the quarter. Organogenesis comprises 2.5% of Soleus Capital Management L.P.’s portfolio, making the stock its 11th biggest holding. Soleus Capital Management L.P. owned approximately 0.10% of Organogenesis worth $39,952,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ORGO. Virtus Investment Advisers Inc. bought a new position in shares of Organogenesis during the fourth quarter valued at $157,000. Squarepoint Ops LLC increased its holdings in Organogenesis by 53.2% in the fourth quarter. Squarepoint Ops LLC now owns 126,791 shares of the company’s stock valued at $406,000 after purchasing an additional 44,051 shares during the period. Two Sigma Investments LP increased its holdings in Organogenesis by 25.9% in the fourth quarter. Two Sigma Investments LP now owns 382,406 shares of the company’s stock valued at $1,224,000 after purchasing an additional 78,744 shares during the period. ProShare Advisors LLC raised its position in Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock worth $65,000 after purchasing an additional 6,689 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Organogenesis by 2.8% during the 4th quarter. Millennium Management LLC now owns 208,420 shares of the company’s stock worth $667,000 after buying an additional 5,765 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Insider Activity at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares of the company’s stock, valued at $851,082.90. This trade represents a 13.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 36.90% of the stock is owned by company insiders.

Organogenesis Stock Performance

Shares of ORGO stock opened at $3.08 on Monday. The stock has a market capitalization of $390.71 million, a PE ratio of -51.33 and a beta of 1.85. The business’s 50 day simple moving average is $4.41 and its 200 day simple moving average is $3.92. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. Organogenesis Holdings Inc. has a one year low of $2.28 and a one year high of $6.71.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.17). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $86.69 million during the quarter, compared to analyst estimates of $90.77 million. As a group, research analysts forecast that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley upped their price target on Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.